A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The researchers then investigated how the metabolisms of treated mice changed. They found that the effect was caused by ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

研究人员选择研究Semaglutide作为潜在治疗方法，因为这一类药物有助于减少MASH患者的脂肪和肝脏疤痕。Newsome教授此前在《柳叶刀》和《新英格兰医学杂志》上发表的小规模积极研究表明，使用Semaglutide治疗MASH对患者有益。

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.